Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Atherosclerosis Reports
Published in: Current Atherosclerosis Reports 4/2012

01-08-2012 | Cardiovascular Disease and Stroke (M Fink and J Safdieh, Section Editors)

Etiologies of Intracerebral Hematomas

Authors: Qingliang T. Wang, Stanley Tuhrim

Published in: Current Atherosclerosis Reports | Issue 4/2012

Login to get access

Abstract

Intracerebral hemorrhage (ICH) remains a life-threatening disease that carries significant morbidity and mortality despite recent diagnostic and management advances. Various conditions are associated with increased risk of intracerebral hemorrhage. Understanding the etiology of these conditions and their pathophysiological contribution to ICH will likely lead to better therapeutic and preventative measures and improve the morbidity and mortality associated with intracerebral hemorrhage. We will review the current literature regarding important etiologies/risk factors of intracerebral hemorrhage.
Literature
1.
2.
Masuhr F, Mehraein S, Einhaupl K. Cerebral venous and sinus thrombosis. J Neurol. 2004;251(1):11–23.PubMedCrossRef
3.
Sayama CM, et al. Capillary telangiectasias: clinical, radiographic, and histopathological features. Clinical article. J Neurosurg. 2010;113(4):709–14.PubMedCrossRef
4.
Tang SC, et al. Diffuse capillary telangiectasia of the brain manifested as a slowly progressive course. Cerebrovasc Dis. 2003;15(1–2):140–2.PubMedCrossRef
5.
6.
van Asch CJ, et al. Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis. Lancet Neurol. 2010;9(2):167–76.PubMedCrossRef
7.
Appelros P, Stegmayr B, Terent A. Sex differences in stroke epidemiology: a systematic review. Stroke. 2009;40(4):1082–90.PubMedCrossRef
8.
9.
Lee WC, et al. Long-term cost of stroke subtypes among Medicare beneficiaries. Cerebrovasc Dis. 2007;23(1):57–65.PubMedCrossRef
10.
11.
Ariesen MJ, et al. Risk factors for intracerebral hemorrhage in the general population: a systematic review. Stroke. 2003;34(8):2060–5.PubMedCrossRef
12.
13.
Zia E, et al. Blood pressure in relation to the incidence of cerebral infarction and intracerebral hemorrhage. Hypertensive hemorrhage: debated nomenclature is still relevant. Stroke. 2007;38(10):2681–5.PubMedCrossRef
14.
Bogucki J, et al. A new CT-based classification of spontaneous supratentorial intracerebral haematomas. Neurol Neurochir Pol. 2009;43(3):236–44.PubMed
15.
16.
Qureshi AI, et al. Isolated and borderline isolated systolic hypertension relative to long-term risk and type of stroke: a 20-year follow-up of the national health and nutrition survey. Stroke. 2002;33(12):2781–8.PubMedCrossRef
17.
18.
Qureshi AI, et al. Intracranial atherosclerotic disease: an update. Ann Neurol. 2009;66(6):730–8.PubMedCrossRef
19.
Vernooij MW, et al. Prevalence and risk factors of cerebral microbleeds: the Rotterdam scan study. Neurology. 2008;70(14):1208–14.PubMedCrossRef
20.
• Poels MM et al. Prevalence and risk factors of cerebral microbleeds: an update of the Rotterdam scan study. Stroke. 2010;41(10 Suppl):S103-6.PubMedCrossRef
21.
Quinones-Hinojosa A, et al. Spontaneous intracerebral hemorrhage due to coagulation disorders. Neurosurg Focus. 2003;15(4):E3.PubMedCrossRef
22.
Rinkel GJ. Natural history, epidemiology and screening of unruptured intracranial aneurysms. J Neuroradiol. 2008;35(2):99–103.PubMedCrossRef
23.
Fisher CM. Hypertensive cerebral hemorrhage. Demonstration of the source of bleeding. J Neuropathol Exp Neurol. 2003;62(1):104–7.PubMed
24.
Rosenblum WI. Fibrinoid necrosis of small brain arteries and arterioles and miliary aneurysms as causes of hypertensive hemorrhage: a critical reappraisal. Acta Neuropathol. 2008;116(4):361–9.PubMedCrossRef
25.
Challa VR, Moody DM, Bell MA. The Charcot-Bouchard aneurysm controversy: impact of a new histologic technique. J Neuropathol Exp Neurol. 1992;51(3):264–71.PubMedCrossRef
26.
Panerai RB. Cerebral autoregulation: from models to clinical applications. Cardiovasc Eng. 2008;8(1):42–59.PubMedCrossRef
27.
Noorani A, Sadat U, Gaunt ME. Cerebral hemodynamic changes following carotid endarterectomy: 'cerebral hyperperfusion syndrome'. Expert Rev Neurother. 2010;10(2):217–23.PubMedCrossRef
28.
Ogasawara K, et al. Intracranial hemorrhage associated with cerebral hyperperfusion syndrome following carotid endarterectomy and carotid artery stenting: retrospective review of 4494 patients. J Neurosurg. 2007;107(6):1130–6.PubMedCrossRef
29.
Dunatov S, Antoncic I, Bralic M. Hemodynamic changes in the posterior cerebral circulation triggered by insufficient sympathetic innervation–cause of primary intracerebral hemorrhage? Med Hypotheses. 2011;76(5):668–9.PubMedCrossRef
30.
Hefzy HM, et al. Hemorrhage in posterior reversible encephalopathy syndrome: imaging and clinical features. AJNR Am J Neuroradiol. 2009;30(7):1371–9.PubMedCrossRef
31.
Kang CK, et al. Hypertension correlates with lenticulostriate arteries visualized by 7T magnetic resonance angiography. Hypertension. 2009;54(5):1050–6.PubMedCrossRef
32.
• Arima H et al. Effects of blood pressure lowering on major vascular events among patients with isolated diastolic hypertension: the perindopril protection against recurrent stroke study (PROGRESS) trial. Stroke. 2011;42(8):2339–41.PubMedCrossRef
33.
Broderick J, et al. Guidelines for the management of spontaneous intracerebral hemorrhage in adults: 2007 update: a guideline from the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group. Stroke. 2007;38(6):2001–23.PubMedCrossRef
34.
• Mayer SA et al. Clinical practices, complications, and mortality in neurological patients with acute severe hypertension: the Studying the Treatment of Acute hyperTension registry. Crit Care Med. 2011;39(10):2330–6.PubMedCrossRef
35.
Ohwaki K, et al. Blood pressure management in acute intracerebral hemorrhage: relationship between elevated blood pressure and hematoma enlargement. Stroke. 2004;35(6):1364–7.PubMedCrossRef
36.
Qureshi AI, Palesch YY. Antihypertensive treatment of acute cerebral hemorrhage (ATACH) II: design, methods, and rationale. Neurocrit Care. 2011;15(3):559–76.PubMedCrossRef
37.
• Qureshi AI et al. Effect of systolic blood pressure reduction on hematoma expansion, perihematomal edema, and 3-month outcome among patients with intracerebral hemorrhage: results from the antihypertensive treatment of acute cerebral hemorrhage study. Arch Neurol. 2010;67(5):570–6.PubMedCrossRef
38.
• Anderson CS et al. Effects of early intensive blood pressure-lowering treatment on the growth of hematoma and perihematomal edema in acute intracerebral hemorrhage: the Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial (INTERACT). Stroke. 2010;41(2):307–12.PubMedCrossRef
39.
Smeda JS, Daneshtalab N. The effects of poststroke captopril and losartan treatment on cerebral blood flow autoregulation in SHRsp with hemorrhagic stroke. J Cereb Blood Flow Metab. 2011;31(2):476–85.PubMedCrossRef
40.
• Witmer C et al. Associations between intracranial haemorrhage and prescribed prophylaxis in a large cohort of haemophilia patients in the United States. Br J Haematol. 2011;152(2):211–6.PubMedCrossRef
41.
42.
Nuss R, Soucie JM, Evatt B. Changes in the occurrence of and risk factors for hemophilia-associated intracranial hemorrhage. Am J Hematol. 2001;68(1):37–42.PubMedCrossRef
43.
del Zoppo GJ, Mori E. Hematologic causes of intracerebral hemorrhage and their treatment. Neurosurg Clin N Am. 1992;3(3):637–58.PubMed
44.
Gronbaek H, et al. Liver cirrhosis, other liver diseases, and risk of hospitalisation for intracerebral haemorrhage: a Danish population-based case–control study. BMC Gastroenterol. 2008;8:16.PubMedCrossRef
45.
Miyasaka M, et al. Vitamin K deficiency bleeding with intracranial hemorrhage: focus on secondary form. Emerg Radiol. 2007;14(5):323–9.PubMedCrossRef
46.
47.
Psaila B, et al. Intracranial hemorrhage (ICH) in children with immune thrombocytopenia (ITP): study of 40 cases. Blood. 2009;114(23):4777–83.PubMedCrossRef
48.
•• Flaherty ML. Anticoagulant-associated intracerebral hemorrhage. Semin Neurol. 2010;30(5):565–72.PubMedCrossRef
49.
• Sonneville R et al. Neurologic complications and outcomes of infective endocarditis in critically ill patients: the ENDOcardite en REAnimation prospective multicenter study. Crit Care Med. 2011;39(6):1474–81.PubMedCrossRef
50.
Kannoth S, et al. Intracranial infectious aneurysm: presentation, management and outcome. J Neurol Sci. 2007;256(1–2):3–9.PubMedCrossRef
51.
• van Beijnum J et al. Treatment of brain arteriovenous malformations: a systematic review and meta-analysis. JAMA. 2011;306(18):2011–9.PubMedCrossRef
52.
Laakso A, et al. Risk of hemorrhage in patients with untreated Spetzler-Martin grade IV and V arteriovenous malformations: a long-term follow-up study in 63 patients. Neurosurgery. 2011;68(2):372–7. discussion 378.PubMedCrossRef
53.
54.
Hoffman C, et al. Associated aneurysms in pediatric arteriovenous malformations and the implications for treatment. Neurosurgery. 2011;69(2):315–22.PubMedCrossRef
55.
Hernesniemi JA, et al. Natural history of brain arteriovenous malformations: a long-term follow-up study of risk of hemorrhage in 238 patients. Neurosurgery. 2008;63(5):823–9. discussion 829–31.PubMedCrossRef
56.
• Washington CW, McCoy KE, Zipfel GJ. Update on the natural history of cavernous malformations and factors predicting aggressive clinical presentation. Neurosurg Focus. 2010;29(3):E7.PubMedCrossRef
57.
Ruiz DS, Yilmaz H, Gailloud P. Cerebral developmental venous anomalies: current concepts. Ann Neurol. 2009;66(3):271–83.PubMedCrossRef
58.
•• Vasileyko V et al. Aging and cerebrovascular dysfunction: contribution of hypertension, cerebral amyloid angiopathy, and immunotherapy. Ann NY Acad Sci. 2010;1207:58–70.CrossRef
59.
Jellinger KA, Lauda F, Attems J. Sporadic cerebral amyloid angiopathy is not a frequent cause of spontaneous brain hemorrhage. Eur J Neurol. 2007;14(8):923–8.PubMedCrossRef
60.
Ritter MA, et al. Role of cerebral amyloid angiopathy in intracerebral hemorrhage in hypertensive patients. Neurology. 2005;64(7):1233–7.PubMedCrossRef
61.
Smith EE, et al. MRI markers of small vessel disease in lobar and deep hemispheric intracerebral hemorrhage. Stroke. 2010;41(9):1933–8.PubMedCrossRef
62.
Potsi S, et al. Superficial cortical siderosis. Acta Neurol Belg. 2011;111(2):162.PubMed
63.
Touze E, et al. Fibromuscular dysplasia of cervical and intracranial arteries. Int J Stroke. 2010;5(4):296–305.PubMedCrossRef
64.
Fukui M. Guidelines for the diagnosis and treatment of spontaneous occlusion of the circle of Willis ('moyamoya' disease). Research Committee on Spontaneous Occlusion of the Circle of Willis (Moyamoya Disease) of the Ministry of Health and Welfare, Japan. Clin Neurol Neurosurg. 1997;99 Suppl 2:S238–40.PubMed
65.
Iwama T, et al. Mechanism of intracranial rebleeding in moyamoya disease. Clin Neurol Neurosurg. 1997;99 Suppl 2:S187–90.PubMedCrossRef
66.
Saeki N, et al. Hemorrhagic type moyamoya disease. Clin Neurol Neurosurg. 1997;99 Suppl 2:S196–201.PubMed
67.
Ceri M et al. Massive intracerebral hemorrhage associated with Wegener granulomatosis. Rheumatol Int. 2011.
68.
Ishikawa K, Matsuura S. Occlusive thromboaortopathy (Takayasu's disease) and pregnancy. Clinical course and management of 33 pregnancies and deliveries. Am J Cardiol. 1982;50(6):1293–300.PubMedCrossRef
69.
Katz JM, Segal AZ. Incidence and etiology of cerebrovascular disease in patients with malignancy. Curr Atheroscler Rep. 2005;7(4):280–8.PubMedCrossRef
70.
Licata B, Turazzi S. Bleeding cerebral neoplasms with symptomatic hematoma. J Neurosurg Sci. 2003;47(4):201–10. discussion 210.PubMed
71.
Turgut M, et al. Pituitary apoplexy: an overview of 186 cases published during the last century. Acta Neurochir (Wien). 2010;152(5):749–61.CrossRef
72.
de San Pedro JR, et al. Massive hemorrhage in hemangioblastomas Literature review. Neurosurg Rev. 2010;33(1):11–26.PubMedCrossRef
73.
Cheng MH, Lin JW. Intracranial meningioma with intratumoral hemorrhage. J Formos Med Assoc. 1997;96(2):116–20.PubMed
74.
Wong PF, et al. Antiplatelet agents for intermittent claudication. Cochrane Database Syst Rev. 2011;11:CD001272.PubMed
75.
•• Geeganage CM et al. Dual or mono antiplatelet therapy for patients with acute ischemic stroke or transient ischemic attack: systematic review and meta-analysis of randomized controlled trials. Stroke. 2012.
76.
Valgimigli M, Minarelli M. Triple antiplatelet therapy in acute coronary syndromes. Drugs. 2011;71(13):1703–19.PubMedCrossRef
77.
Foerch C, et al. Pretreatment with antiplatelet agents is not independently associated with unfavorable outcome in intracerebral hemorrhage. Stroke. 2006;37(8):2165–7.PubMedCrossRef
78.
• Moussouttas M et al. Role of antiplatelet agents in hematoma expansion during the acute period of intracerebral hemorrhage. Neurocrit Care. 2010;12(1):24–9.PubMedCrossRef
79.
•• Hansen ML et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med. 2010;170(16):1433–41.PubMedCrossRef
80.
Qureshi AI, et al. Intracranial hemorrhages associated with intravenous platelet glycoprotein IIB/IIIA receptor inhibitors in the United States. Cardiovasc Drugs Ther. 2005;19(5):371–3.PubMedCrossRef
81.
Zubkov AY, et al. Predictors of outcome in warfarin-related intracerebral hemorrhage. Arch Neurol. 2008;65(10):1320–5.PubMedCrossRef
82.
Cucchiara B, et al. Hematoma growth in oral anticoagulant related intracerebral hemorrhage. Stroke. 2008;39(11):2993–6.PubMedCrossRef
83.
Davis SM, et al. Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage. Neurology. 2006;66(8):1175–81.PubMedCrossRef
84.
Mayer SA, et al. Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2008;358(20):2127–37.PubMedCrossRef
85.
Flaherty ML, et al. Location and outcome of anticoagulant-associated intracerebral hemorrhage. Neurocrit Care. 2006;5(3):197–201.PubMedCrossRef
86.
Hart RG, Boop BS, Anderson DC. Oral anticoagulants and intracranial hemorrhage. Facts and hypotheses. Stroke. 1995;26(8):1471–7.PubMedCrossRef
87.
Connolly SJ, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–51.PubMedCrossRef
88.
•• Prasad V, Kaplan RM, Passman RS. New frontiers for stroke prevention in atrial fibrillation. Cerebrovasc Dis. 2012;33(3):199–208.PubMedCrossRef
89.
Granger CB, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–92.PubMedCrossRef
90.
Patel MR, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–91.PubMedCrossRef
91.
Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med. 1995;333(24):1581–7.
92.
Derex L, Nighoghossian N. Intracerebral haemorrhage after thrombolysis for acute ischaemic stroke: an update. J Neurol Neurosurg Psychiatry. 2008;79(10):1093–9.PubMedCrossRef
93.
Diedler J, et al. Safety of intravenous thrombolysis for acute ischemic stroke in patients receiving antiplatelet therapy at stroke onset. Stroke. 2010;41(2):288–94.PubMedCrossRef
94.
• Goldstein JN et al. Management of thrombolysis-associated symptomatic intracerebral hemorrhage. Arch Neurol. 2010;67(8):965–9.PubMedCrossRef
95.
Morgan T, et al. Preliminary findings of the minimally-invasive surgery plus rtPA for intracerebral hemorrhage evacuation (MISTIE) clinical trial. Acta Neurochir Suppl. 2008;105:147–51.PubMedCrossRef
96.
Morgan T, et al. Preliminary report of the clot lysis evaluating accelerated resolution of intraventricular hemorrhage (CLEAR-IVH) clinical trial. Acta Neurochir Suppl. 2008;105:217–20.PubMedCrossRef
97.
Ngo QN, et al. External ventricular drains in pediatric patients. Pediatr Crit Care Med. 2009;10(3):346–51.PubMedCrossRef
98.
Bouras T, Sgouros S. Complications of endoscopic third ventriculostomy. J Neurosurg Pediatr. 2011;7(6):643–9.PubMedCrossRef
99.
Misaki K, et al. Intracerebral hemorrhage secondary to ventriculoperitoneal shunt insertion–four case reports. Neurol Med Chir (Tokyo). 2010;50(1):76–9.CrossRef
100.
Kimmelman J, et al. Risk of surgical delivery to deep nuclei: a meta-analysis. Mov Disord. 2011;26(8):1415–21.PubMedCrossRef
101.
Seijo FJ, et al. Complications in subthalamic nucleus stimulation surgery for treatment of Parkinson's disease. Review of 272 procedures. Acta Neurochir (Wien). 2007;149(9):867–75. discussion 876.CrossRef
102.
Gooch MR, et al. Complications of cranioplasty following decompressive craniectomy: analysis of 62 cases. Neurosurg Focus. 2009;26(6):E9.PubMedCrossRef
103.
• Toossi S et al. Neurovascular complications of cocaine use at a tertiary stroke center. J Stroke Cerebrovasc Dis. 2010;19(4):273–8.PubMedCrossRef
104.
Pozzi M, Roccatagliata D, Sterzi R. Drug abuse and intracranial hemorrhage. Neurol Sci. 2008;29 Suppl 2:S269–70.PubMedCrossRef
105.
106.
Pedersen HS, et al. N-3 fatty acids as a risk factor for haemorrhagic stroke. Lancet. 1999;353(9155):812–3.PubMedCrossRef
107.
• Westover MB et al. Statin use following intracerebral hemorrhage: a decision analysis. Arch Neurol. 2011;68(5):573–9.PubMedCrossRef
108.
Goldstein LB, et al. Hemorrhagic stroke in the stroke prevention by aggressive reduction in cholesterol levels study. Neurology. 2008;70(24 Pt 2):2364–70.PubMedCrossRef
109.
• Hackam DG, et al. Statins and intracerebral hemorrhage: collaborative systematic review and meta-analysis. Circulation 2011;124(20):2233–42.PubMedCrossRef
110.
Bang OY, et al. Cholesterol level and symptomatic hemorrhagic transformation after ischemic stroke thrombolysis. Neurology. 2007;68(10):737–42.PubMedCrossRef
111.
• Rodriguez-Luna D, et al. Serum low-density lipoprotein cholesterol level predicts hematoma growth and clinical outcome after acute intracerebral hemorrhage. Stroke. 2011;42(9):2447–52.PubMedCrossRef
112.
Bateman BT, et al. Intracerebral hemorrhage in pregnancy: frequency, risk factors, and outcome. Neurology. 2006;67(3):424–9.PubMedCrossRef
113.
Rayes M, et al. Good outcome in HELLP syndrome with lobar cerebral hematomas. Neurocrit Care. 2011;14(2):276–80.PubMedCrossRef
114.
Caprio F, Bernstein RA. Duration of anticoagulation after cerebral venous sinus thrombosis. Neurocrit Care. 2011.
Metadata
Title
Etiologies of Intracerebral Hematomas
Authors
Qingliang T. Wang
Stanley Tuhrim
Publication date
01-08-2012
Publisher
Current Science Inc.
Published in
Current Atherosclerosis Reports / Issue 4/2012
Print ISSN: 1523-3804
Electronic ISSN: 1534-6242
DOI
https://doi.org/10.1007/s11883-012-0253-0

Other articles of this Issue 4/2012

Current Atherosclerosis Reports 4/2012 Go to the issue

Cardiovascular Disease and Stroke (M Fink and J Safdieh, Section Editors)

Management of Acute Hypertensive Response in Patients with Intracerebral Hemorrhage

Cardiovascular Disease and Stroke (M Fink and J Safdieh, Section Editors)

Intracerebral Hemorrhage from Cerebral Venous Thrombosis

Cardiovascular Disease and Stroke (M Fink and J Safdieh, Section Editors)

International Epidemiology of Intracerebral Hemorrhage

Genetics (AJ Marian, Section Editor)

The Enigma of Genetics Etiology of Atherosclerosis in the Post-GWAS Era

Cardiovascular Disease and Stroke (M Fink and J Safdieh, Section Editors)

Nonaneurysmal Subarachnoid Hemorrhage: An Update

Cardiovascular Disease and Stroke (M Fink and J Safdieh, Section Editors)

Clinical Syndromes and Management of Intracerebral Hemorrhage
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits